

# EPILOGUE

The **phenoxodiol** story has spanned 25 years, having its origins in the biological oddity that cancer of the large bowel has a tenuous association with female sex hormone.

What is apparent looking back at this story is not how far we have come, but just how much further we have yet to go. Ten years from now I have little doubt that the 18 chapters of the story to date will be condensed into a single chapter by way of introduction.

I don't know whether the remaining story will be entirely about **phenoxodiol** or more about the family of drugs that it spawned, but I have little doubt that **phenoxodiol** will find its niche in cancer therapy and have a story to tell for many years yet. What that niche and the accompanying story are I am not sure, but I suspect that it will be more in the treatment of early-stage cancer rather than the sort of cancers that the OVATURE study represents. **Phenoxodiol** has one huge advantage ...it can kill cancer cells without harming healthy cells, and it appears to be able to detect and eliminate pre-malignant cells as well as overtly malignant ones. With those unique attributes, I foresee the use of the drug being pushed further back into the carcinogenic process. This is not something that will happen quickly because it will take a significant change in the mindsets of clinicians and regulators alike.

My unflagging belief is that Nature provides us with the tools we need to remain healthy throughout life and that most diseases represent an imbalance in our homeostatic environment. One of those homeostatic tools is the ability of certain plant chemicals to detect and to eliminate early cancerous changes. **Phenoxodiol** simply represents a harnessing and accentuation of that process.

Beyond this simple application, **phenoxodiol** is a starting platform, with drugs such as **triphendiol** and **NV-128** and others yet to be disclosed and others yet to be discovered to follow. What these follow-on drugs are doing is taking isolated aspects of **phenoxodiol** activity and emphasising them to the point that they become new generation drugs.

Ten years from now my expectation is that there will be a family of isoflavonoid drugs that will be used in combination along with other standard chemotherapies, with the combination depending on the type of cancer, its stage of advancement and the phenotype of the tumour.

It is easy to get distracted with a publicly-listed company to think that this is all about share price, capital gains, pension fund values, analysts' reports, and profits. As practical realities as these are, the **phenoxodiol** story has always been about trying to tease out a basic scientific truth of human life and to develop that truth for the benefit of the community.